A major Phase III clinical trial of a tau inhibitor aggregation therapy by Singapore's TauRx failed to meet its primary endpoint, though the work showed…

Singapore-based TauRx will update on Phase III studies of its tau aggregation inhibitor LMTX in a podium presentation at the Alzheimer’s Association…

Biocon said in its first-quarter earnings that biosimilar applications for Humira and Herceptin are due to be filed in the U.S. and EU in the company's…

A Chinese research team from Sichuan University is set for the first in vivo CRISPR trial.

China's Jilin Jian Yisheng Biopharma and the U.S. Army Medical Research Institute of Infectious Diseases showed positive animal test results on an Ebola…

Changzhou Fangyuan Pharma is ready for clinical trials in China to test its nearly decade-long work on a tricky-to-make semisynthetic, methicillin-resistant…

Hanmi Pharmaceutical eyes branded drugs, fast-paced R&D and investment in China to get growth on track.

Military hospitals in China are reportedly offering unapproved immunotherapy and stem cell treatments, promising miracle cures at steep fees.